Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.
Antimicrob Agents Chemother. 2010 Dec;54(12):5209-13. doi: 10.1128/AAC.01051-10. Epub 2010 Oct 4.
Tissue penetration of systemic antibiotics is an important consideration for positive outcomes in diabetic patients. Herein we describe the exposure profile and penetration of tigecycline in the interstitial fluid of wound margins versus that of uninfected thigh tissue in 8 adult diabetic patients intravenously (IV) administered 100 mg and then 50 mg of tigecycline twice daily for 3 to 5 doses. Prior to administration of the first dose, 2 microdialysis catheters were inserted into the subcutaneous tissue, the first within 10 cm of the wound margin and the second in the thigh of the same extremity. Samples for determination of plasma and tissue concentrations were simultaneously collected over 12 h under steady-state conditions. Tissue concentrations were corrected for percent in vivo recovery by the retrodialysis technique. Plasma samples were also collected for determination of protein binding at 1, 6, and 12 h postdose for each patient. Protein binding data were corrected using a fitted polynomial equation. The mean patient weight was 95.1 kg (range, 63.6 to 149.2 kg), the mean patient age was 63.5 ± 9.4 years, and 75% of the patients were males. The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively. Protein binding was nonlinear, with the percentage of free drug increasing with decreasing serum concentrations. Exposure values for thigh tissue and wound tissue were similar (P = 0.986). Mean steady-state tissue concentrations for the thigh and wound were similar at 0.12 ± 0.02 μg/ml, and clearance from the tissues appeared similar to that from plasma. Tissue penetration ratios (tissue fAUC/plasma fAUC) were 99% in the thigh and 100% in the wound (P = 0.964). Tigecycline penetrated equally well into wound and uninfected tissue of the same extremity.
全身用抗生素在糖尿病患者中的组织穿透性是获得良好治疗效果的一个重要考量因素。在此,我们描述了 8 例成年糖尿病患者静脉(IV)给予 100 mg 后再给予 50 mg 替加环素,每日 2 次,共 3-5 剂时,替加环素在伤口边缘的间质液与未感染的大腿组织中的暴露概况和穿透情况。在给予首剂前,将 2 个微透析导管插入皮下组织,第一个导管位于伤口边缘 10 cm 以内,第二个导管位于同一肢体的大腿内。在稳态条件下,通过同时收集 12 小时的组织和血浆样本,来测定组织和血浆浓度。通过逆行透析技术,对组织浓度进行了体内回收率的校正。还在每个患者给药后 1、6 和 12 小时时收集血浆样本,以测定蛋白结合率。使用拟合多项式方程校正蛋白结合数据。患者平均体重为 95.1 kg(范围,63.6-149.2 kg),平均年龄为 63.5 ± 9.4 岁,75%的患者为男性。从 0 到 24 小时的血浆、大腿和伤口游离区浓度-时间曲线下面积(fAUC(0-24))的平均值分别为 2.65 ± 0.33、2.52 ± 1.15 和 2.60 ± 1.02 μg·h/ml。蛋白结合呈非线性,游离药物的百分比随血清浓度的降低而增加。大腿组织和伤口组织的暴露值相似(P = 0.986)。大腿和伤口的组织达到稳态浓度相似,分别为 0.12 ± 0.02 μg/ml,且药物从组织中的清除率与从血浆中的清除率相似。组织穿透率(组织 fAUC/血浆 fAUC)在大腿和伤口处均为 99%(P = 0.964)。替加环素均匀地渗透到同一肢体的伤口和未感染组织中。